Skip to main content
NACFC 2025 Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
Session includes an in person invitee/speaker with CF
Session includes an in person invitee/speaker with CF
Livestreamed Session
Livestreamed Session
Recorded Session
Recorded Session
Session is Ticketed (Must Register for Session through Registration)
Session is Ticketed (Must Register for Session through Registration)
Food Available for Session Attendees
Food Available for Session Attendees
Session Feedback

CLIN
Session Type: Thematic Poster Session

TPS03--Imaging: The Final Frontier | Theater A Exhibit Hall

Thursday, October 23, 2025
2:30 PM - 4:00 PM PDT
Location:Theater A Exhibit Hall

This session features two key components: a poster viewing segment followed by a moderated group discussion. The format is designed to foster meaningful dialogue between authors and attendees, encouraging connections across the presented research. Discussion themes will include novel chest imaging techniques, changes in imaging and clinical outcomes in individuals with CF receiving ETI, and innovative imaging approaches beyond the lungs.

Learning Objectives:

  • Identify and describe emerging chest imaging techniques used in cystic fibrosis (CF) care and their potential clinical applications.
  • Evaluate the impact of elexacaftor/tezacaftor/ivacaftor (ETI) therapy on imaging findings and clinical outcomes in individuals with CF.
  • Explore innovative imaging modalities beyond pulmonary assessment, and discuss their potential role in comprehensive CF management.

Presentations:

  • 2:30 PM - 4:00 PM PDT
    TPS03.1- Changes in lung function and lung ventilation following commencement of elexacaftor/tezacaftor/iIvacaftor in a ≤6 year old cohort

    Speaker: Martin Donnelley, PhD – University of Adelaide / Women's and Children's Hospital

  • 2:30 PM - 4:00 PM PDT
    TPS03.2- Quantitative CT scoring of mucus plugs in people with CF

    Speaker: Margherita S. Silani, MD – University of Milan

  • 2:30 PM - 4:00 PM PDT
    TPS03.3- Structural lung abnormalities in children and adults with cystic fibrosis after ETI using AI automated algorithms

    Speaker: Daan Caudri, MD, PhD – Erasmus MC - Sophia Children's Hospital

  • 2:30 PM - 4:00 PM PDT
    TPS03.4- Elexacaftor/tezacaftor/ivacaftor is associated with improvements in mucus plugging, air trapping and bronchial thickening but not bronchial widening in people with CF aged 12 years and older

    Speaker: Paul McNally – RCSI University of Medicine and Health Sciences

  • 2:30 PM - 4:00 PM PDT
    TPS03.5- Olfactory function and sinonasal opacification improve in young children with CF treated with elexacaftor/tezacaftor/ivacator (ETI)

    Speaker: Eugene Oh, MSE – David Geffen School of Medicine at UCLA

  • 2:30 PM - 4:00 PM PDT
    TPS03.6- Assessment of lung disease in people with CF using electrical impedance tomography

    Speaker: Heather Boas, MD – Dartmouth Health Children's

  • 2:30 PM - 4:00 PM PDT
    TPS03.7- Effect of inhaled dry-powder mannitol on mucociliary clearance in moderate to severe CF lung disease while using elexacaftor/tezacaftor/ivacaftor

    Speaker: Subhashini A. Sellers, MD, MSCR – University of North Carolina at Chapel Hill

  • 2:30 PM - 4:00 PM PDT
    TPS03.8- Body fat distribution impacts glucose and insulin secretory indices in people with CF

    Speaker: Lucia Gonzalez Ramirez – Emory University

  • 2:30 PM - 4:00 PM PDT
    TPS03.9- Do CT images accurately identify inflammatory ‘hotspots’ in the CF lung

    Speaker: Georgia Ann Bateman – Royal College of Surgeons in Ireland

  • 2:30 PM - 4:00 PM PDT
    TPS03.10- Elexacaftor/tezacaftor/ivacaftor reduces bronchial dilatations in adolescents with CF

    Speaker: Isabelle Sermet-Gaudelus, MD, phD – INSERM